Krystal Biotech, Inc. (NASDAQ:KRYS) Given Average Rating of “Buy” by Analysts

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) have been assigned a consensus recommendation of “Buy” from the nine ratings firms that are covering the stock, Marketbeat reports. Nine analysts have rated the stock with a buy rating. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $171.00.

Several brokerages have recently weighed in on KRYS. Guggenheim upped their price target on shares of Krystal Biotech from $130.00 to $175.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Stifel Nicolaus reaffirmed a “buy” rating and set a $204.00 target price (up previously from $178.00) on shares of Krystal Biotech in a research report on Tuesday, April 16th. Citigroup boosted their price target on Krystal Biotech from $160.00 to $195.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. HC Wainwright reaffirmed a “buy” rating and set a $200.00 price objective on shares of Krystal Biotech in a research report on Monday. Finally, William Blair reiterated an “outperform” rating on shares of Krystal Biotech in a research note on Tuesday, February 27th.

Krystal Biotech Stock Performance

Shares of KRYS stock opened at $155.68 on Friday. The stock has a 50 day moving average price of $163.46 and a 200 day moving average price of $131.32. Krystal Biotech has a 52-week low of $82.09 and a 52-week high of $189.97. The firm has a market capitalization of $4.44 billion, a P/E ratio of 1,946.24 and a beta of 0.85.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, February 26th. The company reported $0.30 earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.82. The company had revenue of $42.14 million for the quarter, compared to the consensus estimate of $27.43 million. During the same period in the prior year, the firm posted ($1.25) EPS. As a group, sell-side analysts forecast that Krystal Biotech will post 1.89 EPS for the current year.

Insider Activity at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $170.96, for a total transaction of $4,274,000.00. Following the completion of the sale, the insider now owns 1,550,882 shares of the company’s stock, valued at $265,138,786.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Monday, March 11th. The shares were sold at an average price of $170.96, for a total transaction of $4,274,000.00. Following the sale, the insider now owns 1,550,882 shares of the company’s stock, valued at approximately $265,138,786.72. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CAO Kathryn Romano sold 5,000 shares of the company’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $165.88, for a total transaction of $829,400.00. Following the sale, the chief accounting officer now directly owns 12,936 shares of the company’s stock, valued at approximately $2,145,823.68. The disclosure for this sale can be found here. In the last quarter, insiders have sold 38,087 shares of company stock valued at $6,210,591. 14.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On Krystal Biotech

A number of institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its position in Krystal Biotech by 40.7% in the third quarter. Vanguard Group Inc. now owns 2,400,142 shares of the company’s stock worth $278,416,000 after acquiring an additional 693,852 shares during the period. Jennison Associates LLC lifted its stake in shares of Krystal Biotech by 112.5% in the 4th quarter. Jennison Associates LLC now owns 724,344 shares of the company’s stock valued at $89,862,000 after purchasing an additional 383,495 shares during the last quarter. First Turn Management LLC acquired a new position in shares of Krystal Biotech in the 4th quarter valued at $30,045,000. Fred Alger Management LLC grew its holdings in shares of Krystal Biotech by 4,608.6% during the 3rd quarter. Fred Alger Management LLC now owns 167,485 shares of the company’s stock worth $19,428,000 after purchasing an additional 163,928 shares during the period. Finally, Eventide Asset Management LLC acquired a new stake in shares of Krystal Biotech during the 4th quarter worth about $16,932,000. Hedge funds and other institutional investors own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).